XPhyto Therapeutics provides update on their oral film drug delivery platform with Vektor Pharma
XPhyto Therapeutics (CSE: XPHY-OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to provide a look at their German subsidiary, Vektor Pharma who is currently
advancing two sublingual ODF development programs for the delivery of the active
pharmaceutical ingredients.
Rogers telling Proactive the program is on track and a European human study for its sublingual CBD product is planned for Q1 2021 with results expected in Q2 2021.
.
advancing two sublingual ODF development programs for the delivery of the active
pharmaceutical ingredients.
Rogers telling Proactive the program is on track and a European human study for its sublingual CBD product is planned for Q1 2021 with results expected in Q2 2021.
.
People In This Video
No users are tagged in this video
